19 December 2020 in Cureus
Parvovirus B19 (PVB19) is a deoxyribonucleic acid (DNA) virus, the only member of the Parvoviridae, which has a direct cytopathic effect on erythroid progenitor cells, resulting in an arrest of hematopoiesis and subsequent anemia. Less frequently, neutropenia and thrombocytopenia have been reported with the PVB19 infection. We report a rare case of chronic neutropenia due to PVB19 in a human immunodeficiency virus (HIV) patient. A 51-year-old male with a medical history of HIV presented to the Emergency Department (ED) with complaints of generalized weakness. His laboratory tests were significant for severe anemia and new neutropenia. PVB19 DNA by polymerase chain reaction (PCR) was positive. PVB19 immunoglobulin M (IgM) and IgG were reported negative. He was diagnosed with aplastic anemia from PVB19 and neutropenia. From June 2013 to January 2019, the patient was admitted 23 times with severe neutropenia and anemia, and on each occasion, PVB19 DNA by PCR was positive. During these multiple admissions, he was treated with antibiotics for neutropenic fever, methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and methicillin-sensitive Staphylococcus aureus (MSSA) skin abscesses. On each occasion, he required multiple blood transfusions, and he received intravenous immunoglobulin (IVIG) that resulted in significant improvement of absolute neutrophil count (ANC) count. He had bone biopsy twice, which showed normal maturation of the myeloid series and reduced erythroid progenitor cells consistent with PVB19 infection. PVB19 DNA by PCR remains positive to date. Immunocompromised individuals usually develop a chronic infection from PVB19, and rarely infection with PVB19 can cause severe neutropenia that can be long-lasting and life-threatening. Early recognition and treatment with IVIG are the key to improve the clinical outcome.
26 October 2022 in Infectious Diseases in Clinical Practice
Background Double anaerobic coverage is often used for intra-abdominal infections postoperatively. The primary objective of this study was evaluating length of hospital stay, in-hospital postoperative complications, and readmission within 30 days of discharge due to postoperative complications in patients who received piperacillin/tazobactam versus piperacillin/tazobactam plus metronidazole for intra-abdominal infections. The secondary objective was comparing in-hospital mortality and hospital-associated Clostridioides difficile infection between the 2 groups. Methods This retrospective cohort study included adults, who received either single or double anaerobic coverage postoperatively for at least 48 hours between January 1, 2016, and June 30, 2019. Statistical analysis involved matching patients 1:1 between the 2 groups based on Charlson Comorbidity Index, American Society of Anesthesiologists physical status classification, and surgical wound classification. Descriptive statistics and logistic regression were used to analyze the outcomes. Results Of 163 patients, 134 were matched 1:1 into single and double anaerobic coverage groups. The baseline characteristics of each group were similar except for diagnosis. Double anaerobic coverage was more often used for gastrointestinal perforations (38.8% vs 16.4%, P = 0.004) and single anaerobic coverage for acute cholecystitis (37.3% vs 9%, P < 0.001). In a multivariate analysis, double anaerobic coverage was associated with longer length of hospital stay (P = 0.003) compared with single anaerobic coverage. In-hospital mortality (6%) and hospital-associated C. difficile (1.5%) infection were only observed in the double anaerobic coverage group. Conclusions Double anaerobic coverage is associated with longer length of hospital stay and in-hospital postoperative complications.